1. Home
  2. ELEV vs GENK Comparison

ELEV vs GENK Comparison

Compare ELEV & GENK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELEV
  • GENK
  • Stock Information
  • Founded
  • ELEV 2019
  • GENK 2011
  • Country
  • ELEV United States
  • GENK United States
  • Employees
  • ELEV N/A
  • GENK N/A
  • Industry
  • ELEV Biotechnology: Pharmaceutical Preparations
  • GENK Restaurants
  • Sector
  • ELEV Health Care
  • GENK Consumer Discretionary
  • Exchange
  • ELEV Nasdaq
  • GENK Nasdaq
  • Market Cap
  • ELEV 18.1M
  • GENK 21.2M
  • IPO Year
  • ELEV 2021
  • GENK 2023
  • Fundamental
  • Price
  • ELEV $0.32
  • GENK $4.24
  • Analyst Decision
  • ELEV Buy
  • GENK Strong Buy
  • Analyst Count
  • ELEV 6
  • GENK 2
  • Target Price
  • ELEV $2.94
  • GENK $10.00
  • AVG Volume (30 Days)
  • ELEV 753.5K
  • GENK 145.8K
  • Earning Date
  • ELEV 08-05-2025
  • GENK 07-30-2025
  • Dividend Yield
  • ELEV N/A
  • GENK 0.71%
  • EPS Growth
  • ELEV N/A
  • GENK N/A
  • EPS
  • ELEV N/A
  • GENK N/A
  • Revenue
  • ELEV N/A
  • GENK $214,957,000.00
  • Revenue This Year
  • ELEV N/A
  • GENK $16.62
  • Revenue Next Year
  • ELEV N/A
  • GENK $20.40
  • P/E Ratio
  • ELEV N/A
  • GENK N/A
  • Revenue Growth
  • ELEV N/A
  • GENK 14.40
  • 52 Week Low
  • ELEV $0.22
  • GENK $3.16
  • 52 Week High
  • ELEV $3.77
  • GENK $11.16
  • Technical
  • Relative Strength Index (RSI)
  • ELEV 49.38
  • GENK 54.09
  • Support Level
  • ELEV $0.29
  • GENK $3.16
  • Resistance Level
  • ELEV $0.32
  • GENK $4.37
  • Average True Range (ATR)
  • ELEV 0.02
  • GENK 0.30
  • MACD
  • ELEV 0.00
  • GENK 0.09
  • Stochastic Oscillator
  • ELEV 59.01
  • GENK 89.26

About ELEV Elevation Oncology Inc. Common stock

Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.

About GENK GEN Restaurant Group Inc.

GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. It operates 43 Gen Korean BBQ restaurants in the United States.

Share on Social Networks: